Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 27;13(1):e063675.
doi: 10.1136/bmjopen-2022-063675.

Construct validity of Patient-Reported Outcomes Measurement Information System Paediatric measures in juvenile idiopathic arthritis and systemic lupus erythematosus: cross-sectional evaluation

Elissa R Weitzman  1   2   3 , Amy Gaultney  4 , Emily von Scheven  5 , Sarah Ringold  6 , Courtney M Mann  7 , Kara M Magane  8 , Li Lin  7 , Renee Leverty  9 , Anne Dennos  9 , Alexy Hernandez  7 , Steven J Lippmann  7 , Fatma Dedeoglu  10 , Alexandra C Marin  8   2 , Rachele Cox  8 , Bryce B Reeve  7   9   11 , Laura E Schanberg  9   11
Affiliations

Construct validity of Patient-Reported Outcomes Measurement Information System Paediatric measures in juvenile idiopathic arthritis and systemic lupus erythematosus: cross-sectional evaluation

Elissa R Weitzman et al. BMJ Open. .

Abstract

Objectives: Evaluate construct validity of Patient-Reported Outcomes Measurement Information System (PROMIS) Paediatric measures of symptoms and functioning against measures of disease activity among youth with juvenile idiopathic arthritis (JIA) or systemic lupus erythematosus (SLE).

Design: Cross-sectional associations among PROMIS measures and clinical metrics of disease activity were estimated.

Setting: Seven clinical sites of the Childhood Arthritis and Rheumatology Alliance (CARRA) in the USA.

Participants: Youth aged 8-17 years enrolled in the CARRA Registry.

Intervention: PROMIS measures were collected and associations with clinical measures of disease activity estimated, by condition, in bivariate and multivariable analyses with adjustment for sociodemographics, insurance status, medications and disease duration.

Main outcome measures: PROMIS Paediatric measures of mobility, physical activity, fatigue, pain interference, family relationships, peer relationships, depressive symptoms, psychological stress, anxiety, and meaning and purpose, and clinical metrics of disease.

Results: Among 451 youth (average age 13.8 years, 71% female), most (n=393, 87%) had a JIA diagnosis and the remainder (n=58, 13%) had SLE. Among participants with JIA, those with moderate/high compared with low/inactive disease had, on average, worse mobility (multivariable regression coefficient and 95% CIs) (-7.40; -9.30 to -5.50), fatigue (3.22; 1.02 to 5.42), pain interference (4.76; 3.04 to 6.48), peer relationships (-2.58; -4.52 to -1.64), depressive symptoms (3.00; 0.96 to 5.04), anxiety (2.48; 0.40 to 4.56) and psychological stress (2.52; 0.68 to 4.36). For SLE, youth with active versus inactive disease had on average worse mobility (-5.07; -10.15 to 0.01) but PROMIS Paediatric measures did not discriminate participants with active and inactive disease in adjusted analyses.

Conclusions: Seven PROMIS Paediatric measures discriminated between active and inactive disease in youth with JIA. Results advance the usefulness of PROMIS for understanding well-being and improving interventions for youth with JIA, but larger studies are needed to determine utility in SLE cohorts.

Trial registration number: National Institute of Arthritis and Musculoskeletal and Skin Diseases (U19AR069522).

Keywords: EPIDEMIOLOGY; Health informatics; Paediatric rheumatology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Two authors have conflicts of interest: SR has salary support from CARRA and is co-PI of a PCORI-funded study that is receiving a study drug (abatacept) from Bristol Myers Squibb. Both SR and FD receive royalties from UpToDate, a Wolters Kluwer evidence-based clinical decision support resource.

References

    1. Oen K, Guzman J, Dufault B, et al. . Health-Related quality of life in an inception cohort of children with juvenile idiopathic arthritis: a longitudinal analysis. Arthritis Care Res (Hoboken) 2018;70:134–44. 10.1002/acr.23236. - DOI - PubMed
    1. McDougall J, DeWit DJ, Nichols M, et al. . Three-Year trajectories of global perceived quality of life for youth with chronic health conditions. Qual Life Res 2016;25:3157–71. 10.1007/s11136-016-1353-z. - DOI - PMC - PubMed
    1. Listing M, Mönkemöller K, Liedmann I, et al. . The majority of patients with newly diagnosed juvenile idiopathic arthritis achieve a health-related quality of life that is similar to that of healthy Peers: results of the German multicenter inception cohort (icon). Arthritis Res Ther 2018;20:106. 10.1186/s13075-018-1588-x. - DOI - PMC - PubMed
    1. Weitzman ER, Wisk LE, Salimian PK, et al. . Adding patient-reported outcomes to a multisite registry to quantify quality of life and experiences of disease and treatment for youth with juvenile idiopathic arthritis. J Patient Rep Outcomes 2018;2:1. 10.1186/s41687-017-0025-2. - DOI - PMC - PubMed
    1. Hanns L, Cordingley L, Galloway J, et al. . Depressive symptoms, pain and disability for adolescent patients with juvenile idiopathic arthritis: results from the childhood arthritis prospective study. Rheumatology (Oxford) 2018;57:1381–9. 10.1093/rheumatology/key088. - DOI - PMC - PubMed

Publication types